IL13RA2 and glioblastoma: Recent studies have focused on applying the success of immune therapies within GBM populations; a recent single patient case report demonstrated significant GBM tumor regression following IL13Rα2-targeted chimeric antigen receptor (CAR)–engineered T cells therapy administration, with subsequent host-immune response increases sustaining 7.5 months post-treatment (13).